This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (111)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Experiences With G 32883

SIGFRID BLOM, MD

Arch Neurol. 1963;9(3):285-290.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The numerous different types of operation described for trigeminal neuralgia are an indication of the therapeutic difficulties encountered with this disease. Even if several good methods of operation exist, they all have certain disadvantages that prevent them from enbeing ideal.

The drugs reported as having any effect are few, and all of them either have proved toxic with long-term therapy or have had excessive secondary effects.

A therapeutically practical method would seem to be to block the mechanism that gives rise to the attacks of pain, or—to put it another way—to find a means of blocking both normal and pathological transmission in synapses in the trigeminal area. At the same time, the drug used should be selective, so as not to have any marked effect on other cerebral functions, and it should be possible to give it over a long period. To be regarded as specific and safe, such a drug . . . [Full Text PDF of this Article]

Author Affiliations
UPPSALA, SWEDEN

Department of Neurology, Akademiska sjukhuset.

Footnotes
Submitted for publication April 17, 1963; accepted June 8.

Geigy 32883 will be released under the name of Tegretol.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?